This clinical trial focuses on children with juvenile idiopathic arthritis, a type of arthritis that affects children and causes joint inflammation and stiffness. The study aims to explore the effects of withdrawing medications early in children who have been in clinical remission, meaning their disease is inactive, for at least six months. The medications being studied include Cosentyx (secukinumab), Olumiant (baricitinib), Reumaflex (methotrexate), Enbrel (etanercept), RoActemra (tocilizumab), XELJANZ (tofacitinib), Simponi (golimumab), and ORENCIA (abatacept). Some participants will continue their medication as usual, while others will stop taking it earlier, guided by specific tests and imaging results.

The purpose of the study is to determine if stopping medication early, based on certain health markers, is safe and more effective than the standard practice of maintaining the same treatment for a longer period. Participants will be randomly assigned to either continue their medication or to stop it early. Throughout the study, the health of the participants will be closely monitored to see if their arthritis symptoms return, which is known as a flare-up. The study will compare the number of flare-ups and the time it takes for them to occur between the two groups.

This trial is designed to help understand if early withdrawal of medication can be a safe and effective option for children with juvenile idiopathic arthritis who are in remission. The study will use advanced techniques like imaging and multi-Omics, which involves analyzing various biological data, to guide the decision on when to stop the medication. The findings could lead to more personalized treatment plans for children with this condition.